---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-012242"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2024-04-17T23:59:59+00:00"
generated_at: "2026-06-03T22:00:51.329147+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Windtree Therapeutics reports Q4 2023 net loss of $5.2M; cash only $4.3M as of Dec 31

## Summary
- Q4 net loss $5.2M ($0.95 per share) vs $9.7M ($13.01) in Q4 2022; FY net loss $20.3M ($5.24 per share).
- Cash and equivalents $4.3M at Dec 31, 2023; completed $1.5M convertible note bridge in April 2024 to fund operations through April.
- Acquired novel aPKCi inhibitor platform from Varian Biopharmaceuticals; includes topical and oral formulations.
- Licensed istaroxime and other CV assets to Lee's Pharmaceutical for Greater China; eligible for up to $138M milestones plus royalties.
- Two Phase 2 istaroxime trials in cardiogenic shock ongoing; data expected H2 2024.

## SEC filing metadata
- accession: 0001437749-24-012242
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2024-04-17T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774924012242/0001437749-24-012242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774924012242/wint20231117_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-012242
- JSON: https://secwatch.observer/filing/0001437749-24-012242.json
- Plain text: https://secwatch.observer/filing/0001437749-24-012242.txt

## Key facts
- Earnings Releases
  WINDTREE THERAPEUTICS INC /DE/ reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
  - Period: the fourth quarter and fiscal year ended December 31, 2023
  - Result: reported results
  source text: On April 17, 2024, Windtree Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/946486/000143774924012242/0001437749-24-012242-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.